GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Book Value per Share

Syndax Pharmaceuticals (STU:1T3) Book Value per Share : €2.31 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Book Value per Share?

Syndax Pharmaceuticals's book value per share for the quarter that ended in Mar. 2025 was €2.31.

During the past 12 months, Syndax Pharmaceuticals's average Book Value Per Share Growth Rate was -56.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Syndax Pharmaceuticals was 80.70% per year. The lowest was -137.60% per year. And the median was 7.20% per year.

Syndax Pharmaceuticals's current price is €9.60. Its book value per share for the quarter that ended in Mar. 2025 was €2.31. Hence, today's PB Ratio of Syndax Pharmaceuticals is 4.15.

During the past 13 years, the highest P/B Ratio of Syndax Pharmaceuticals was 11.86. The lowest was 1.36. And the median was 3.58.


Syndax Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Syndax Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Book Value per Share Chart

Syndax Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.33 6.57 6.48 5.99 3.21

Syndax Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.33 4.75 3.87 3.21 2.31

Competitive Comparison of Syndax Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Syndax Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's PB Ratio falls into.


;
;

Syndax Pharmaceuticals Book Value per Share Calculation

Syndax Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(275.16-0.00)/85.69
=3.21

Syndax Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(198.93-0.00)/86.05
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Syndax Pharmaceuticals  (STU:1T3) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Syndax Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals Business Description

Traded in Other Exchanges
Address
730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines